Live Breaking News & Updates on Astellas Gene Therapies Inc

Stay updated with breaking news from Astellas gene therapies inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Astellas to pump $352 million into Irish manufacturing facility

The Japanese firm Astellas Pharma will apply for planning permission to construct a drug manufacturing facility in Tralee, Co. Kerry, Ireland worth around €330 million ($352 million). ....

Michael Lohan , Eli Lilly , Novo Nordisk , Industrial Development Authority , Leadership In Energy , Kerry Technology Park , Boehringer Ingelheim , South West , Environmental Design , Active Pharmaceutical Ingredients , Markets Amp Regulations , Clinical Development , Contract Manufacturing Amp Logistics ,

EMA Validates Type II Variation Application for Enzalutamide in Nonmetastatic Hormone-Sensitive Prostate Cancer

The European Medicines Agency has validated its Type II variation for enzalutamide as an option in patients with nonmetastatic hormone-sensitive prostate cancer at high risk of biochemical recurrence who are not suitable for salvage radiotherapy. ....

United States , Ahsan Arozullah , Astella Xtandi , Almeida Luz , Oncology Department At Astellas Pharma Inc , European Medicines Agency , European Union , Astellas Pharma Inc , Pfizer Inc , Oncology Department , Astellas Pharma , Medicines Agency , Nonmetastatic Hormone Sensitive Prostate Cancer ,

Sandoz concludes acquisition of antifungal agent Mycamine from Astellas

Basel: Sandoz has successfully completed the acquisition of worldwide brand rights for systemic antifungal agent Mycamine (micafungin sodium, Funguard in Japan) from Astellas.Through this acquisition. ....

Richard Saynor , Sandoz News , Micafungin Sodium , Invasive Candidiasis , Esophageal Candidiasis ,

Astellas invests $50m to support advancement of Poseida's cancer cell therapy

Astellas invests $50m to support advancement of Poseida's cancer cell therapy
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Mark Gergen , Adam Pearson , Astellas Pharma , Poseida Therapeutics , Focus Area Approach , Roche Therapeutics ,

Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy

Poseida is a clinical-stage biotechnology company dedicated to advancing a new class of cancer cell therapy and gene therapy products using genetic engineering technologies Astellas to invest a total of $50 million to acquire approximately 8.8% of Poseida and to receive a right of exclusive negotiation and first refusal for any potential partnering of P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy product candidate for solid tumors Astellas will have the right to designate an obser. ....

Naoki Okamura , Mark Gergen , Adam Pearson , Poseida Therapeutics Inc , Exchange Commission , Astellas Pharma Inc , Support Poseida , Redefining Cancer Cell , Poseida Board , Poseida Therapeutics , Focus Area Approach , Astella Primary Focuses , Chief Strategy Officer , Chief Executive , Site Specific Gene Editing , Looking Statements , Private Securities Litigation Reform Act , Press Release Image , Clinical Stage , P Muc1c Allo1 , Ar T , Press Release , Ews Release ,